Precigen, Inc. (NASDAQ:PGEN - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 1,162,796 shares changed hands during trading, a decline of 18% from the previous session's volume of 1,424,528 shares.The stock last traded at $1.89 and had previously closed at $1.70.
Wall Street Analyst Weigh In
PGEN has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and set a $6.00 price objective on shares of Precigen in a research note on Thursday, March 20th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Precigen in a research note on Thursday, May 15th. JMP Securities reiterated a "market outperform" rating and set a $6.00 price objective on shares of Precigen in a research note on Thursday, June 12th. Finally, Wall Street Zen downgraded Precigen from a "hold" rating to a "sell" rating in a report on Saturday, May 24th.
Get Our Latest Research Report on PGEN
Precigen Stock Up 11.8%
The stock has a market capitalization of $560.84 million, a P/E ratio of -3.39 and a beta of 1.78. The business has a fifty day moving average price of $1.45 and a 200-day moving average price of $1.46.
Precigen (NASDAQ:PGEN - Get Free Report) last posted its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. Precigen had a negative return on equity of 279.20% and a negative net margin of 3,728.87%. The company had revenue of $1.34 million for the quarter, compared to the consensus estimate of $0.50 million. On average, equities analysts expect that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new position in shares of Precigen in the fourth quarter worth about $27,000. Envestnet Asset Management Inc. raised its stake in shares of Precigen by 29.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock worth $30,000 after buying an additional 5,915 shares during the period. Boothbay Fund Management LLC bought a new position in shares of Precigen in the fourth quarter worth about $35,000. Apella Capital LLC bought a new position in shares of Precigen in the first quarter worth about $40,000. Finally, RPO LLC bought a new position in shares of Precigen in the fourth quarter worth about $47,000. Institutional investors own 33.51% of the company's stock.
Precigen Company Profile
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Read More
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
